JP2021506898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506898A5 JP2021506898A5 JP2020534265A JP2020534265A JP2021506898A5 JP 2021506898 A5 JP2021506898 A5 JP 2021506898A5 JP 2020534265 A JP2020534265 A JP 2020534265A JP 2020534265 A JP2020534265 A JP 2020534265A JP 2021506898 A5 JP2021506898 A5 JP 2021506898A5
- Authority
- JP
- Japan
- Prior art keywords
- form according
- solution
- crystalline form
- crystal
- values
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 34
- 239000013078 crystal Substances 0.000 claims description 27
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609512P | 2017-12-22 | 2017-12-22 | |
| US62/609,512 | 2017-12-22 | ||
| PCT/US2018/066769 WO2019126482A1 (en) | 2017-12-22 | 2018-12-20 | Crystalline forms of nicotinamide riboside chloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506898A JP2021506898A (ja) | 2021-02-22 |
| JP2021506898A5 true JP2021506898A5 (https=) | 2021-11-18 |
Family
ID=66993830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534265A Pending JP2021506898A (ja) | 2017-12-22 | 2018-12-20 | ニコチンアミドリボシドクロリドの結晶形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11414407B2 (https=) |
| EP (1) | EP3727400A4 (https=) |
| JP (1) | JP2021506898A (https=) |
| CN (1) | CN112020363A (https=) |
| CA (1) | CA3086535A1 (https=) |
| WO (1) | WO2019126482A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180303861A1 (en) | 2017-04-24 | 2018-10-25 | Eric Marcotulli | Treating and preventing kidney damage |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| EP3999518A2 (en) | 2019-07-19 | 2022-05-25 | Biosynth AG | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof |
| CN111454311B (zh) * | 2020-04-03 | 2021-10-19 | 深圳市迪克曼科技开发有限公司 | 烟酰胺核糖的有机酸盐及其组合物与制备方法 |
| CN111808156A (zh) * | 2020-07-15 | 2020-10-23 | 许昌远志生物科技有限公司 | 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法 |
| WO2024259359A2 (en) | 2023-06-14 | 2024-12-19 | ChromaDex Inc. | Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1190080A (en) | 1966-08-08 | 1970-04-29 | Kyowa Hakko Kogyo Company Ltd | Process for producing Nicotinamide Adenine Dinucleotide |
| US3728111A (en) | 1971-09-21 | 1973-04-17 | Asea Ab | Method of manufacturing billets from powder |
| CN1262556C (zh) | 1997-02-06 | 2006-07-05 | 印斯拜尔药品股份有限公司 | 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用 |
| GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| JP3748536B2 (ja) | 2001-02-09 | 2006-02-22 | 三共株式会社 | ピリミジンヌクレオシド誘導体の結晶 |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20050020587A1 (en) | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| EP1723227A4 (en) | 2004-02-10 | 2007-09-19 | Dartmouth College | NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE |
| US8114626B2 (en) | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| CN1964627B (zh) | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| JP4058106B2 (ja) | 2005-02-18 | 2008-03-05 | アストラゼネカ アクチボラグ | 抗菌性のピペリジン誘導体 |
| EP2805719A1 (en) | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| US20070149466A1 (en) | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| CN101360421B (zh) | 2005-11-18 | 2014-06-18 | 康乃尔研究基金会有限公司 | 烟酰核苷组合物及其使用方法 |
| AU2006339607A1 (en) | 2005-12-02 | 2007-09-13 | Sirtris Pharmaceuticals, Inc. | Modulators of Cdc2-like kinases (Clks) and methods of use thereof |
| WO2007136744A1 (en) | 2006-05-19 | 2007-11-29 | The Johns Hopkins University | Crystal structure of a substrate complex of nampt/pbef/visfatin |
| CA2672373C (en) | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| US20100047177A1 (en) | 2007-01-26 | 2010-02-25 | Washington University | Methods and compositions for treating neuropathies |
| CA2725481A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| WO2010002586A2 (en) | 2008-06-30 | 2010-01-07 | Elc Management Llc | Topical compositions comprising isonicotinamide |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
| US20120164670A1 (en) | 2009-06-23 | 2012-06-28 | President And Fellows Of Harvard College | Methods and kits for measuring enzyme activity |
| EP2456772A4 (en) | 2009-07-24 | 2013-02-27 | Amazentis Sa | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONSERVING HEALTH HEALTH IN NEURODEEGENERATIVE DISEASES |
| US8507251B2 (en) | 2009-09-28 | 2013-08-13 | Robert J. Greenstein | Medium and method for culturing Mycobacterium avium subspecies paratuberculosis |
| US9603862B2 (en) | 2009-12-14 | 2017-03-28 | Cornell University | Activation and activators of SIRT5 |
| US20130165398A1 (en) | 2010-03-29 | 2013-06-27 | Paul Hochegger | Concentration-enhancing drink |
| US8481711B2 (en) | 2010-07-06 | 2013-07-09 | Hidenori Kamanishi | Neurite outgrowth agent |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| US20120107888A1 (en) | 2011-02-17 | 2012-05-03 | Qteros, Inc. | Modulation of fermentation products through vitamin supplementation |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| CA2840516A1 (en) | 2011-06-29 | 2013-01-03 | President And Fellows Of Harvard College | Small molecule cd38 inhibitors and methods of using same |
| US20140256760A1 (en) | 2012-07-09 | 2014-09-11 | Noglo Llc | Reduction or prevention of alcohol reaction with dietary supplements |
| CN110051672A (zh) | 2012-07-09 | 2019-07-26 | 诺格罗有限责任公司 | 使用膳食补充剂预防酒精反应 |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| WO2014059029A1 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function |
| WO2014111906A1 (en) | 2013-01-21 | 2014-07-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | Bioluminescence imaging of small biomolecules |
| CN105228627B (zh) | 2013-03-15 | 2018-07-13 | 纽斯尔特科学公司 | 亮氨酸和烟酸降低脂质水平 |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| KR101914844B1 (ko) | 2013-10-24 | 2018-11-02 | 더 프록터 앤드 갬블 캄파니 | 피부 미백 화장 조성물 및 방법 |
| KR20150050406A (ko) | 2013-10-29 | 2015-05-08 | 한림대학교 산학협력단 | 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물 |
| CA2928656C (en) | 2013-10-30 | 2020-07-28 | ChromaDex Inc. | Nicotinamide riboside compositions for topical use in treating skin conditions |
| MX373132B (es) | 2013-11-12 | 2020-05-25 | Ortho Nutra Llc | Suplemento a base de teacrina y método de uso del mismo. |
| WO2015099842A1 (en) | 2013-12-23 | 2015-07-02 | Abbott Laboratories | Hot beverage fortifier |
| AU2015229055B2 (en) | 2014-03-13 | 2019-09-12 | Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US20150297508A1 (en) | 2014-04-21 | 2015-10-22 | William Andriette | Topical Formulation to Enhance Genital Sensation and Function |
| KR20170012449A (ko) * | 2014-06-02 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 결정질 베타-d-니코틴아미드 리보시드의 제조 및 용도 |
| CN107073027A (zh) | 2014-07-17 | 2017-08-18 | 斯克利普斯研究院 | 增强癌症疗法的方法和组合物 |
| CN106715454B (zh) * | 2014-07-24 | 2020-06-16 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
| KR102629310B1 (ko) * | 2015-03-09 | 2024-01-24 | 더블유.알. 그레이스 앤드 캄파니-콘. | 니코틴아미드 리보사이드의 결정 형태 |
| CN115176998A (zh) * | 2016-04-14 | 2022-10-14 | 可劳迈戴斯有限公司 | 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸和烟碱基化合物衍生物在婴儿配方中的用途 |
| WO2017218580A1 (en) * | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
| CA3045876A1 (en) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| EP3727400A4 (en) | 2017-12-22 | 2021-10-20 | Elysium Health, Inc. | CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE |
| EP3999518A2 (en) | 2019-07-19 | 2022-05-25 | Biosynth AG | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof |
| CN111808156A (zh) | 2020-07-15 | 2020-10-23 | 许昌远志生物科技有限公司 | 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法 |
-
2018
- 2018-12-20 EP EP18892817.0A patent/EP3727400A4/en not_active Withdrawn
- 2018-12-20 WO PCT/US2018/066769 patent/WO2019126482A1/en not_active Ceased
- 2018-12-20 CA CA3086535A patent/CA3086535A1/en active Pending
- 2018-12-20 JP JP2020534265A patent/JP2021506898A/ja active Pending
- 2018-12-20 US US16/955,412 patent/US11414407B2/en active Active
- 2018-12-20 CN CN201880090063.7A patent/CN112020363A/zh active Pending
-
2022
- 2022-08-12 US US17/887,060 patent/US12043616B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506898A5 (https=) | ||
| CN103201262B (zh) | 自分泌运动因子抑制剂及其用途 | |
| CN1243541C (zh) | 2－(α－羟基戊基)苯甲酸盐及其制法和用途 | |
| JP2021504310A5 (https=) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2015520151A5 (https=) | ||
| CN108349906B (zh) | 依托咪酯衍生物及其中间体、制备方法和用途 | |
| JP2022523368A5 (https=) | ||
| JP2013519665A (ja) | メシル酸イマチニブのα形の製造方法 | |
| JP2020519569A (ja) | ベンゾフラン誘導体遊離塩基の結晶およびその製造方法 | |
| WO2020020230A1 (zh) | 一类双阳离子化合物及其制备方法和用途 | |
| JP2013511475A5 (https=) | ||
| JP5550644B2 (ja) | （１ｒ，２ｓ，３ｒ）−１−（２−（イソオキサゾール−３−イル）−１ｈ−イミダゾール−４−イル）ブタン−１，２，３，４−テトラオールの固体形態及びその使用方法 | |
| JP6310923B2 (ja) | ジヒドロピリミジン誘導体の結晶形 | |
| CN103923168B (zh) | 一种阿加曲班一水合物的制备方法 | |
| WO2008051637A2 (en) | Pyridazinone compounds | |
| JP3353784B2 (ja) | 公知のブラジキニン拮抗剤のガラス体 | |
| JP2021513963A (ja) | 異常増殖性疾患を治療するための薬剤および方法 | |
| WO2019037161A1 (zh) | 一种合成氯法齐明关键中间体n-(4-氯苯基)-1，2-苯二胺的方法 | |
| WO2017020869A1 (zh) | 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺的晶型b及其制备方法和应用 | |
| CN120204220A (zh) | 治疗及/或预防纤维性疾病的胺基萘醌化合物 | |
| CN104326983A (zh) | 一种塞来昔布的精制方法 | |
| CN105440045B (zh) | 一种纳布啡酸式盐的精制工艺 | |
| CN1944448A (zh) | 葛根素衍生物及其药物用途 | |
| JP2020512975A5 (https=) |